Navigation Links
Valeant Pharmaceuticals To Syndicate Incremental Loans
Date:9/14/2012

MONTREAL, Sept. 14, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced plans to syndicate an additional $1,000,000,000 of incremental term B loans under its existing senior secured credit facilities.  The incremental term B loans will be used to provide a portion of the financing for Valeant's anticipated acquisition of all of the outstanding common stock of Medicis Pharmaceutical Corporation (NYSE: MRX). The incremental term B loans will have a seven year term and are expected to have terms that are substantially similar to the Company's existing Term Loan B facility. The incremental term B loans are expected to close in the first half of 2013, concurrent with the closing of the transaction. The Company also intends, subject to market and other conditions, to raise approximately $500,000,000 of unsecured debt for general corporate purposes, including acquisitions.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Forward-looking Statements

This press release may contain forward-looking statements.  Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements which include statements regarding our plans to syndicate incremental term loans and the proposed terms thereof and our expectation as to when and if the incremental term loan facility will close, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and risks and uncertainties as detailed from time to time in the Company's filings with the SEC and the Canadian Securities Administrators ("CSA"), which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Announces Management Change
2. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
3. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
5. Valeant Pharmaceuticals To Host Investor Day
6. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
7. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
8. Isis Pharmaceuticals Completes Redemption Of 2 5/8% Convertible Subordinated Notes Due 2027
9. Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
10. Gerri Henwood Joins Actinium Pharmaceuticals as Chief Development Officer
11. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) has ... 2016 Top Workplaces National Standard. To learn ... ... (PRNewsFoto/Diplomat Pharmacy, Inc.) ... an employee survey administered by WorkplaceDynamics, LLC, a research firm specializing ...
(Date:12/8/2016)... 8 de dezembro de 2016  A Mederi Therapeutics Inc . anunciou ... tratamento não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto ... ... Live Stretta procedure performed and broadcast during the ... Wuhan Union Hospital ...
(Date:12/8/2016)... DANVILLE, Pa. , Dec. 8, 2016  A ... physicians reports that the use of opioid therapy to ... actually increase the likelihood of more harmful consequences, including ... Davis , M.D., and Zankhana Mehta , M.D., ... current research on chronic opioid therapy. The study was ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... The Dan Carlisle Agency, an ... County, is announcing the launch of a charity drive to raise support and ... women and children in Birmingham has grown steadily since the 1980’s, and the ...
(Date:12/8/2016)... Louis, MS (PRWEB) , ... December 08, 2016 , ... ... that serve commercial and residential clients in and around the Hancock County area, is ... for the Hancock County Food Pantry. , The Hancock County Food Pantry has worked ...
(Date:12/7/2016)... ... December 07, 2016 , ... DrugDev again demonstrated its dedication to ... of the early adopters completing EU-U.S. Privacy Shield Certification from the U.S. Department of ... both sides of the Atlantic with a mechanism to comply with EU data protection ...
(Date:12/7/2016)... ... December 07, 2016 , ... Kenall Manufacturing, a leader in sealed healthcare lighting ... MPCNGX is a multi-function, sealed, LED luminaire that meets the needs of everyone in ... it’s needed. , A 2’ x 4’ model features four modes: reading, ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... Smart Device Remote Control through a new partnership with Splashtop Inc. This remote ... its mobile solutions to help businesses maximize their uptime and productivity. , Wavelink ...
Breaking Medicine News(10 mins):